IRBM | No Hype. Just Great Science. Drug Discovery on a Mission.
Discover IRBM’s expertise through a wide range of content covering various therapeutic areas and the latest drug discovery techniques. Gain insights into how we tackle challenges, drive …
About Us - IRBM
IRBM is a leading research organization with extensive experience in transforming early-stage science into advanced drug discovery programs. Specializing in cancer, neurological …
Join Us - IRBM
At IRBM, we offer you not only a job but an inspiring, dynamic and supportive work environment that encourages innovation, collaboration, and personal growth. Some of the key benefits of …
Our History - IRBM
IRBM was established in 1990 as a molecular biology institute, a joint venture between Merck & Co. and the Italian chemical company, Sigma-Tau. In 2000, Merck & Co. obtained sole …
Latest News - IRBM
Discover IRBM’s expertise through a wide range of content covering various therapeutic areas and the latest drug discovery techniques. Gain insights into how we tackle challenges, drive …
SHP2 Inhibitors: Progress and Perspectives in 2024 - IRBM
2024年4月24日 · In the evolving landscape of cancer therapy, the discovery of a brain permeable SHP2i (I-1000233) by scientists at IRBM marks a significant step forward, particularly for novel …
Contact - IRBM
IRBM accelerates your drug discovery projects from bold ideas to clinical-ready candidates. With our deep expertise, proven collaborations, and a history of developing transformative …
Our Capabilities - IRBM
Discover IRBM’s expertise through a wide range of content covering various therapeutic areas and the latest drug discovery techniques. Gain insights into how we tackle challenges, drive …
Publications - IRBM
Discover IRBM’s expertise through a wide range of content covering various therapeutic areas and the latest drug discovery techniques. Gain insights into how we tackle challenges, drive …
Peptide Drug Discovery - IRBM
At IRBM, we harness our world-class expertise in the development of safe and effective peptide therapeutics. Our team has extensive knowledge in peptide and macrocyclic drugs.